Excell Technology Ventures, a community development venture capital firm based in Rochester, NY, has invested a total of $1.85 million in three early-stage life sciences startups through the Upstate Biotech Venture Fund (UBV), a collaborative fund launched in partnership with Upstate Medical University, the SUNY Research Foundation, CNY Biotech Accelerator, Empire State Development, and Excell Technology Ventures.
The investment was distributed through three startups based in New York State: Dub Therapeutics who created sdRNA, a medicine used to treat diseases that cause scarring in the body, Mimivax, a immunotherapeutic vaccine designed to leverage the body’s immune system to treat and prevent cancer, and sayhii, a AI-powered personal coaching platform.
These investments will accelerate commercialization, scale operations, and strengthen Upstate New York’s economy across critical healthcare sectors and foster job creation in historically underserved regions of New York.
Excell Technology Ventures is a CDVCA member fund and an investee of CDVCA InnovateNY Fund. For more information, visit Excell Technology Ventures, MimiVax, sayhii, and DUB Therapeutics.